An RCT with the combination of varenicline and bupropion for smoking cessation: clinical implications for front line use.

ABSTRACT:

Background and aims

Despite the availability of several efficacious smoking cessation treatments, fewer than 25% of smokers who quit remain abstinent 1 year post-treatment. This study aimed to determine if varenicline and bupropion combination treatment would result in higher abstinence rates than varenicline alone.

Design

A double-blind, randomized, parallel-group smoking cessation clinical trial in which participants were exposed to 12 weeks of treatment and followed for 12 months.

Setting

Hospital-based out-patient clinic in Texas, USA specializing in cancer prevention.

Participants

A total of 385 community smokers (58.44% male) who smoked 1 pack of cigarettes/day [mean = 19.66 cigarettes/day, standard deviation (SD) = 9.45]; had average carbon monoxide (CO)

SUBMITTER: Cinciripini PM 

PROVIDER: S-EPMC6196126 | biostudies-literature | 2018 Apr

REPOSITORIES: biostudies-literature